Growth strong Emerging SCINTIX therapy platform with FDA clearance and ongoing product expansion as evidenced by the launch of RefleXion X2 to enhance tumor detection and visualization, signaling opportunities to engage hospital systems and cancer centers investing in next generation radiotherapy technology.

Strategic funding Significant funding activity including a $105 million equity raise and a robust funding total of $675M, indicating strong investor confidence and potential for growth-driven procurement cycles in large health networks and hospital systems.

Clinical partnerships Recent acquisitions related to radiopharmaceutical rights and emphasis on biology-guided radiotherapy suggests collaboration opportunities with radiopharmacies, oncology clinics, and integrated care networks seeking advanced theranostic solutions.

Healthcare reimbursement Experienced leadership in patient access and reimbursement with a senior director of patient access and a background in securing coverage for radiation oncology technologies, presenting a pathway to navigate payer strategies for new therapy adoption.

Enterprise tech readiness Tech stack including Salesforce, AWS, Azure, SAP, and ELK indicates scalable enterprise operations; leverage this to position RefleXion as a compatible partner for large multisite deployments, data integration, and hospital IT alignment in sales conversations.